Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ropivacaine hydrochloride monohydrate (LEA-103 HCl) is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
10 mg | 在庫あり | ¥ 7,500 | |||
25 mg | 在庫あり | ¥ 11,000 | |||
50 mg | 在庫あり | ¥ 16,500 | |||
100 mg | 在庫あり | ¥ 22,500 | |||
200 mg | 在庫あり | ¥ 35,500 | |||
500 mg | 在庫あり | ¥ 60,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 10,000 |
説明 | Ropivacaine hydrochloride monohydrate (LEA-103 HCl) is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly. |
ターゲット&IC50 | TREK1 (COS-7 cell membrane):402.7 μM (IC50) |
In vitro | Raltitrexed induces double-stranded DNA breaks in a concentration-dependent manner. In Lovo cells and LS174T cell lines containing wild-type p53, Raltitrexed increases the levels of the Bax protein up to 5-fold. In human colon cancer cells, Raltitrexed is actively absorbed into cells and is then rapidly and extensively metabolized into a series of polyglutamates, which results in the effective inhibition of thymidylate synthase. Raltitrexed is delivered to the brain very quickly and can be detected in all brain tissues within 5 minutes. In human colon cancer cells, the combination of Raltitrexed and SN-38 results in a synergistic cytotoxic effect within a range of concentrations. Raltitrexed is a specific folate-based inhibitor of thymidylate synthase. The effect on the activity of advanced rectal cancer is similar to fluorouracil (5-fluorouracil) plus leucovorin. Raltitrexed produces activity by rapid cell entry and glutamination. The glutaminated derivatives are more than 100 times more active than the parent compound. In the HCT-8 cell line, Raltitrexed results in an increase in intracellular phosphoribosyl pyrophosphate (PRPD) indicating that the cytotoxic effect of Raltitrexed in combination with 5-FU is due to increased nucleotide formation of 5-FU. Combinations of Raltitrexed and folinic acid (5FU-FA) show a combination of mode-dependent, synergistic inhibition of proliferation, which is determined by measuring the combination series. Raltitrexed combined with Vorinostat produced significant synergistic effects of cell cycle perturbation and S-phase arrest. |
別名 | Ropivacaine HCl, Ropivacaine HCl monohydrate, LEA 103, LEA-103 HCl |
分子量 | 328.88 |
分子式 | C17H29ClN2O2 |
CAS No. | 132112-35-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 62 mg/mL (199.44 mM)
H2O: 46 mg/mL (147.97 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ropivacaine hydrochloride monohydrate 132112-35-7 Membrane transporter/Ion channel Sodium Channel Potassium Channel LEA-103 hypertension Ropivacaine HCl Ropivacaine HCl monohydrate Na channels pain K(2P) neuropathic Inhibitor vasoconstrictive KcsA Ropivacaine hydrochloride Monohydrate Na+ channels Ropivacaine HCl Monohydrate potassium Ropivacaine Hydrochloride TREK-1 inhibit conduction LEA 103 Ropivacaine hydrochloride LEA103 channel neuronal LEA-103 HCl inhibitor